Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anne Marie Sobiesk"'
Autor:
Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi
Publikováno v:
NEJM Evidence. 2
Autor:
Sonia Dolfi, Tracy Tang, Georgina Long AO, Paolo Ascierto, F Stephen Hodi, Evan Lipson, Dirk Schadendorf, John Wojcik, Jennifer Postelnek, Yu Wang, Anne Marie Sobiesk, Kaushal Mishra, Sarah Keidel, Karen Miller-Moslin, Hussein Tawbi, Charlie Garnett-Benson
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Hussein A, Tawbi, Dirk, Schadendorf, Evan J, Lipson, Paolo A, Ascierto, Luis, Matamala, Erika, Castillo Gutiérrez, Piotr, Rutkowski, Helen J, Gogas, Christopher D, Lao, Juliana Janoski, De Menezes, Stéphane, Dalle, Ana, Arance, Jean-Jacques, Grob, Shivani, Srivastava, Mena, Abaskharoun, Melissa, Hamilton, Sarah, Keidel, Katy L, Simonsen, Anne Marie, Sobiesk, Bin, Li, F Stephen, Hodi, Georgina V, Long, Sajeve, Thomas
Publikováno v:
The New England journal of medicine. 386(1)
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking a
Autor:
Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Sarah Keidel, Karin Jonczak, Anne Marie Sobiesk, Sonia Dolfi, Georgina V. Long
Publikováno v:
Journal of Clinical Oncology. 40:9505-9505
9505 Background: In the phase 2/3 RELATIVITY-047 trial, NIVO + RELA as a fixed-dose combination (FDC) significantly improved the primary endpoint of progression-free survival (PFS) versus NIVO in patients (pts) with previously untreated metastatic or
Autor:
Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi
Publikováno v:
Journal of Clinical Oncology. 40:360385-360385
360385 Background: RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination (FDC) demonstrated a significan